KALA BIO, Inc. Cash Flow Statement
KALA|1 years of annual SEC 10-K data (FY2017-FY2017)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
KALA BIO, Inc. used $15M in operating cash flow and negative free cash flow of $15M in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.02 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 |
|---|---|
| Net Income | -$16.7M |
| Depreciation & Amortization | $330.0K |
| Operating Cash Flow | -$15.1M |
| Capital Expenditures | $252.0K |
| Free Cash Flow | -$15.3M |
| FCF Margin | -34091.1% |